{
    "clinical_study": {
        "@rank": "100956", 
        "arm_group": [
            {
                "arm_group_label": "Aerolized lucinactant low dose", 
                "arm_group_type": "Experimental", 
                "description": "Low Dose of lucinactant for inhalation with nCPAP"
            }, 
            {
                "arm_group_label": "Aerosolized lucinactant middle dose", 
                "arm_group_type": "Experimental", 
                "description": "Middle dose of lucinactant for inhalation with nCPAP"
            }, 
            {
                "arm_group_label": "Aerosolized lucinactant high dose", 
                "arm_group_type": "Experimental", 
                "description": "High dose of lucinactant for inhalation with nCPAP"
            }, 
            {
                "arm_group_label": "nCPAP alone", 
                "arm_group_type": "Active Comparator", 
                "description": "nCPAP therapy alone"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the safety and tolerability of a single\n      exposure of aerosolized surfactant, specifically lucinactant for inhalation, administered in\n      escalating inhaled doses to preterm neonates 29 to 32 weeks gestational age who are\n      receiving nasal continuous positive airway pressure (nCPAP) for respiratory distress\n      syndrome (RDS), compared to neonates receiving nCPAP alone."
        }, 
        "brief_title": "Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Respiratory Distress Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Respiratory Distress Syndrome, Newborn", 
                "Respiratory Distress Syndrome, Adult"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent from a legally authorized representative\n\n          -  Gestational age 29 to 32 completed weeks (32 weeks 6 days) post menstrual age (PMA)\n\n          -  Successful implementation of controlled nCPAP within 60 minutes after birth\n\n          -  Spontaneous breathing\n\n          -  Chest radiograph consistent with RDS\n\n          -  Need for moderate levels of supplemental oxygen and nCPAP to maintain oxygen\n             saturation of 88%  to 95% for at least 60 minutes within the first 21 hours after\n             birth\n\n        Exclusion Criteria:\n\n          -  Heart rate that cannot be stabilized above 100 beats/minute within 5 minutes of birth\n\n          -  Recurrent episodes of apnea occurring after the initial newborn resuscitation period\n             (ie, 10 minutes after birth) requiring intermittent positive pressure breaths using\n             inflating pressures above the set CPAP pressure administered manually or mechanically\n             through any patient interface\n\n          -  A 5 minute Apgar score < 5\n\n          -  Major congenital malformation(s) and cranial/facial abnormalities that preclude\n             nCPAP, diagnosed antenatally or immediately after birth\n\n          -  Other diseases or conditions potentially interfering with cardiopulmonary function\n             (eg, hydrops fetalis or congenital infection such as toxoplasmosis, rubella,\n             cytomegalovirus, herpes simplex [TORCH])\n\n          -  Known or suspected chromosomal abnormality or syndrome\n\n          -  Prolong rupture of membranes (PROM) > 2 weeks\n\n          -  Evidence of hemodynamic instability requiring vasopressors or steroids for\n             hemodynamic support\n\n          -  Need for endotracheal intubation and mechanical ventilation\n\n          -  Has been administered: another investigational agent or exposure to a medical device,\n             any other surfactant agent, steroid treatment after birth"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Hours", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02074059", 
            "org_study_id": "03-CL-1201", 
            "secondary_id": "1R44HL107000-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Aerolized lucinactant low dose", 
                    "Aerosolized lucinactant middle dose", 
                    "Aerosolized lucinactant high dose"
                ], 
                "description": "Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)", 
                "intervention_name": "Lucinactant for Inhalation", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "nCPAP alone", 
                "description": "nCPAP therapy", 
                "intervention_name": "nCPAP alone", 
                "intervention_type": "Device", 
                "other_name": "nasal continuous positive airway pressure"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Kathy.Arnell@sharp.com", 
                    "last_name": "Kathy Arnell, RNC-NIC", 
                    "phone": "858-939-4966"
                }, 
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92123"
                    }, 
                    "name": "Sharp Mary Birch Hospital for Women and Newborns"
                }, 
                "investigator": {
                    "last_name": "Anup Katheria, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "IMcKay@med.miami.edu", 
                    "last_name": "Isabelle McKay, MS", 
                    "phone": "305-585-6527"
                }, 
                "facility": {
                    "address": {
                        "city": "Maimi", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "University of Miami"
                }, 
                "investigator": {
                    "last_name": "Cristina Naverrete, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lcsmiley@iu.edu", 
                    "last_name": "Lucy Smiley, CCRC", 
                    "phone": "317-278-7364"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Riley Hospital for Children, University of Indiana"
                }, 
                "investigator": {
                    "last_name": "Shawn Ahlfeld, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Evelyn.Migaki@providence.org", 
                    "last_name": "Annie Migaki", 
                    "phone": "503-476-6606"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97225"
                    }, 
                    "name": "Providence St. Vincent Medical Center"
                }, 
                "investigator": {
                    "last_name": "Joseph W Kaempf, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates", 
        "overall_official": {
            "affiliation": "Discovery Laboratories, Inc.", 
            "last_name": "Robert Segal, MD, FACP", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessed during dosing by recording adverse reactions, oxygen saturation levels, and serum electrolytes; and following dosing by recording complications of prematurity and signs of worsening respiratory distress as evidenced by need for increased respiratory support and supplemental oxygen.\"", 
            "measure": "Safety and Tolerability of Lucinactant for Inhalation", 
            "safety_issue": "Yes", 
            "time_frame": "Day 7"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02074059"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Discovery Laboratories, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Discovery Laboratories, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}